Menu

Error message

The specified file temporary://fileyHTr4O could not be copied, because the destination directory is not properly configured. This may be caused by a problem with file or directory permissions. More information is available in the system log.

Detection of mutations of the calreticuline (CALR)

Technology description

Myeloproliferative neoplasms are chronic myeloid cancers divided in Philadelphia positive (Ph+) or negative causing in this case: polycythemia vera (PV) essential thrombocythemia (ET), and primary myelofibrosis (PMF). Most Ph- cases have an activating JAK2 or MPL mutation. Recently, somatic mutations in the calreticulin gene (CALR) have been detected in 56–88% of JAK2/MPL-negative patients affected by ET or PMF.
The inventors have developed a novel detection assay in order to identify the two most common mutations: type-1 and 2 CALR mutations by PNA directed PCR clamping. The assay resulted to be more sensitive, specific and cheaper than Sanger sequencing and it could be applied even in laboratories lacking a basic Sanger sequencing service, a scenario quite common in small laboratories especially those located in developing countries. The method displays a quite high sensitivity, allowing to detect an amount of mutated template as low as 10% for CALR type-1 and 0,1% for CALR type-2 mutations, which cannot be identified by Sanger sequencing. Our diagnostic test shows a sensitivity of 100% (CI 79.41% to 100.00%) and a specificity of 98,5% (CI 91.96% to 99.96%) with an AUC corresponding to 0.99.

Applications

Diagnostic tool for Philadelphia chromosome negative myeloproliferative neoplasms

Key advantages
  • Discriminates 3 mutated forms of the CALR gene from its wild type form
  • Faster and cheaper 
  • High sensitivity 
  • High specificity
Inventors
Filing date and application number

Filing date: 26/04/2016

Application number: 102016000042586

 

Available

Yes

Ownership

Università degli Studi di Torino